Aduro Biotech (ADRO) Sees IPO Price of $17/Share

Aduro Biotech, Inc. (Nasdaq: ADRO) filed an amended registration with the U.S. SEC for an IPO of its Common Stock. The company plans to offer 7 million common shares and sees an offering price of $17 per share. The company plans to list on the Nasdaq Global Market under the symbol, "ADRO."

The offering is being made via BofA Merrill Lynch, Leerink Partners, William Blair, and Canaccord Genuity.

Aduro Biotech is a clinical-stage immuno-oncology company focused on the development of first-in-class technology platforms designed to stimulate robust and durable immune responses against cancer, and our lead product candidate is in a randomized controlled Phase 2b clinical trial in metastatic pancreatic cancer.

You May Also Be Interested In